COMMUNIQUÉS West-GlobeNewswire

Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting

11/12/2017 - 22:30

Preclinical data show dual inhibition of MDM2 and MDMX restores p53 function Data demonstrate strong anti-cancer effects in models of T-cell lymphomas and acute myeloid leukemia ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE [...]

Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting

11/12/2017 - 22:30

Columbia University reports Caelum Biosciences’ CAEL-101 was well tolerated, demonstrated early and clinically efficacious organ response in Phase 1a/1b trial in AL amyloidosis City of Hope announces Mustang Bio’s MB- [...]

Minerva Neurosciences Names Richard Russell President

11/12/2017 - 22:30

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV ), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]

Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis

11/12/2017 - 22:21

CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI ), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to [...]

AGTC to Present at BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14, 2017

11/12/2017 - 22:20

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC ), a biotechnology company conducting human clinical trials of adeno-associated virus ( [...]

Avinger Announces Change in Board Leadership

11/12/2017 - 22:15

REDWOOD CITY, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR ) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that [...]

Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M

11/12/2017 - 22:15

Analysis of patient data from a large U.S. library revealed that twenty-five percent of Multiple Myeloma patients have CD33 expression on their multiple myeloma cells supporting the rational for targeting this antigen [...]

Wright Medical Group N.V. to Present at 36th Annual J.P. Morgan Healthcare Conference

11/12/2017 - 22:15

AMSTERDAM, The Netherlands, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ: WMGI ) announced today that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, [...]

argenx announces launch of proposed public offering in the United States

11/12/2017 - 22:11

Regulated information - Inside information December 11, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep pipeline of [...]

Data from Phase 1 Studies of Ivosidenib or Enasidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation

11/12/2017 - 22:05

- Ivosidenib and Enasidenib Evaluated in Combination with Standard Induction (7+3) Chemotherapy or Azacitadine in Newly Diagnosed Patients From Two Phase 1 Studies - - Phase 3 Trial of Ivosidenib or Enasidenib Combined [...]

Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments

11/12/2017 - 22:05

-- Avid Bioservices Records Revenues of $12.8 Million in the Second Quarter of FY2018 -- -- Transition to a Dedicated CDMO Business Nearing Completion -- TUSTIN, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine [...]

Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer

11/12/2017 - 22:05

BURLINGTON, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq: FLXN ) today announced that Scott Kelley, M.D., has been named Chief Medical Officer. Dr. Kelley previously served as the company’ [...]

OrthoPediatrics Corp. Launches New Wrist Fusion Plate System

11/12/2017 - 22:05

WARSAW, Ind., Dec. 11, 2017 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (NASDAQ: KIDS ), a company exclusively focused on advancing the field of pediatric orthopedics, is pleased to announce the launch of its pediatric- [...]

Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting

11/12/2017 - 22:04

SAN DIEGO and TORONTO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO ) (TSX: APS ) today announced the presentation of preclinical data from research led by The University of Texas MD Anderson [...]

OHSU and Aptose Present CG’806 Preclinical Data at ASH 59th Annual Meeting

11/12/2017 - 22:04

PORTLAND, Ore. and SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- The OHSU Knight Cancer Institute and Aptose Biosciences Inc. (NASDAQ: APTO ) (TSX: APS ) today announced the presentation of preclinical data demonstrating [...]

Transparency notification

11/12/2017 - 22:02

Mechelen, Belgium; 11 December 2017; 22.01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Fidelity Management & Research (FMR) LLC. Pursuant to [...]

Achaogen Appoints Blake Wise Chief Executive Officer

11/12/2017 - 22:01

- Dr. Kenneth Hillan to become President, R&D - - Succession designed to lead Achaogen through next phase of growth as a commercial-stage company - - Transition effective January 1, 2018 - SOUTH SAN FRANCISCO, Calif [...]

Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering

11/12/2017 - 22:01

EXTON, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC ), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today [...]

Investors Initiate Tender Offer to Take BioCanCell Private Ahead of Planned Fundraising Round

11/12/2017 - 22:01

JERUSALEM, Dec. 11, 2017 (GLOBE NEWSWIRE) -- BioCanCell Ltd. (TASE: BICL ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer, [...]